Affiliation: Forest Research Institute
- Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezilAntonia P Periclou
Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ 07311 4994, USA
Ann Pharmacother 38:1389-94. 2004..Memantine, a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, was approved in the US for treatment of moderate to severe Alzheimer's disease in October 2003...
- Pharmacokinetic study of memantine in healthy and renally impaired subjectsAntonia Periclou
Forest Research Institute, Jersey City, NJ, USA
Clin Pharmacol Ther 79:134-43. 2006..Our objective was to evaluate the pharmacokinetics of the Alzheimer's disease treatment memantine in subjects with normal and impaired renal function...
- Effects of milnacipran on cardiac repolarization in healthy participantsAntonia Periclou
Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ 07311, USA
J Clin Pharmacol 50:422-33. 2010..9 ms (90% CI: -6.6 to 8.3). The results suggest that milnacipran would not significantly affect cardiac repolarization at clinically relevant therapeutic and supratherapeutic concentrations...